Search results for "monoclonal antibodie"
showing 5 items of 25 documents
Migraine and cluster headache – the common link
2018
Abstract Although clinically distinguishable, migraine and cluster headache share prominent features such as unilateral pain, common pharmacological triggers such glyceryl trinitrate, histamine, calcitonin gene-related peptide (CGRP) and response to triptans and neuromodulation. Recent data also suggest efficacy of anti CGRP monoclonal antibodies in both migraine and cluster headache. While exact mechanisms behind both disorders remain to be fully understood, the trigeminovascular system represents one possible common pathophysiological pathway and network of both disorders. Here, we review past and current literature shedding light on similarities and differences in phenotype, heritability…
The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies.
2021
Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are approved for the European market for a broad range of clinical indications. In order to ensure clinical efficacy and safety aspects, (pre-)clinical experimental approaches evaluate the respective modes of action (MoA). In addition to antigen-specificity including binding affinity and -avidity, MoA comprise Fc-mediated effector functions such as antibody dependent cellular cytotoxicity (ADCC) and the closely related antibody dependent cellular phagocytosis (ADCP). For this reason, a variety of cell-based assays have…
Monoklonālās antivielas - mūsdienu ārstēšanas iespējas
2018
Biozāles ir viens no straujāk augošajiem farmaceitiskās rūpniecības segmentiem veselības aprūpē. Rekombinantās DNS tehnoloģijas un hibridomu tehnoloģijas progress, ir izraisījis liela mēroga proteīnu ražošanu, kuriem ir potenciāli terapeitiski pielietojumi. Kopš 1975. gada, kad pirmo reizi ziņots par monoklonālo antivielu (moAv) attīstību, pagājuši vairāk kā 40 gadi un apmēram 100 terapeitiskās moAv ir apstiprinātas kā zāles, kuras galvenokārt pielieto onkoloģisku un autoimūnu slimību terapijā. Šī pētījuma mērķis bija apzināt ārstu zināšanas par moAv un, noskaidrot ārstu pieredzi un iespējas moAv terapijas pielietošanai Latvijā. Tika veikta aptauja, kurā piedalījās 67 respondenti. Pēc aptau…
RSV disease in infants and young children: Can we see a brighter future?
2022
Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations and 120,000 deaths annually among children <5 years of age. The majority of the burden of RSV occurs in previously healthy infants. Only a monoclonal antibody (mAb) has been approved against RSV infections in a restricted group, leaving an urgent unmet need for a large number of children potentially benefiting from preventive measures. Approaches under development include maternal vaccines to protect newborns, extended half-life monoclon…
Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma
2021
BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of…